Showing results (111-120 of 6,499) with videos related to

Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|June 9, 2016
Uncoupling protein 2 regulates metabolic reprogramming and fate of antigen-stimulated CD8+ T cellsLeena Chaudhuri, Rupesh K Srivastava, Ferdynand Kos, et al.
Cancer Immunology, Immunotherapy : CII|June 14, 2016
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysisMarkus V Heppt, Thomas K Eigentler, Katharina C Kähler, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Intrapleural and intravenous Corynebacterium parvum in patients with resected stage I and II non-small cell carcinoma of the lung. The Ludwig Lung Cancer Study Group
Cancer Immunology, Immunotherapy : CII|August 5, 2017
Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in miceSofie Denies, Bregje Leyman, Hanne Huysmans, et al.
Cancer Immunology, Immunotherapy : CII|September 17, 2017
Monitoring the response of urothelial precancerous lesions to Bacillus Calmette-Guerin at the proteome level in an in vivo rat modelKerem Teke, Nil Guzel, Ali Kemal Uslubas, et al.
Cancer Immunology, Immunotherapy : CII|September 27, 2017
Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancerJitka Fucikova, Michal Podrazil, Ladislav Jarolim, et al.
Cancer Immunology, Immunotherapy : CII|September 1, 2017
Toll-like receptor 5 and 7 expression may impact prognosis of HPV-positive oropharyngeal squamous cell carcinoma patientsLauri Jouhi, Hesham Mohamed, Antti Mäkitie, et al.
Cancer Immunology, Immunotherapy : CII|July 10, 2016
Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansionWei Wang, Amy K Erbe, Kory A Alderson, et al.
Cancer Immunology, Immunotherapy : CII|September 8, 2017
Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignanciesPaulina Nowakowska, Annette Romanski, Nicole Miller, et al.
Cancer Immunology, Immunotherapy : CII|September 13, 2017
Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV diseaseStefan Diem, Omar Hasan Ali, Christoph J Ackermann, et al.
Pageof 650